A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Inclusion Criteria:

• All participants must have a negative pregnancy test at the Screening Visit and onadmission to the Clinical Unit.

• Females of childbearing potential must not be lactating and if heterosexuallyactive, must agree to use an approved method of highly effective contraception. o Hormonal contraceptives and estrogen-containing hormonal methods of birth controlare not permitted due to potential effect and influence on the results using a CoCassessment.

• Females of non-childbearing potential must be confirmed at the Screening Visit.

• Have a Body Mass Index (BMI) between 25 and 40 kg/m2, both inclusive and weigh atleast 60 kg.

Exclusion Criteria:

• History of any clinically important disease or disorder (gastroparesis, deep veinthrombosis, venous thromboembolism, previous surgery of the upper gastrointestinaltract, cardiovascular disease, neuromuscular or neurogenic disease, severe vitamin Ddeficiency (cohort 1 and cohort 2), type I or type II diabetes mellitus, glycatedhemoglobin (HbA1c) ≥ 6.5% at screening, history of neoplastic disease, basalcalcitonin level >50 ng/L (50 pg/L) at screening (cohort 2 and cohort 3), history ofacute or chronic pancreatitis or pancreatic amylase or lipase >2×ULN at screening (cohort 2 and cohort 3), prior history of cholecystectomy or untreatedcholelithiasis and personal or family history of medullary thyroid cancer (MTC) ormultiple endocrine neoplasia type 2 (MEN2) (cohort 2 and cohort 3).

• History or presence of gastrointestinal, hepatic, or renal disease or any othercondition known to interfere with absorption, distribution, metabolism, or excretionof drugs.

• Any clinically important illness, medical/surgical procedure, or trauma.

• Any laboratory values with deviations or clinically important abnormalities inclinical chemistry, hematology, or urinalysis.

• Any positive result on screening for serum Hepatitis B surface antigen (HBsAg),Hepatitis B core antibody (HBcAb) or Human immunodeficiency virus (HIV).

• Abnormal vital signs.

• Any clinically important abnormalities in rhythm, conduction, or morphology of theresting 12 lead electrocardiogram (ECG), at screening.

• Current smokers or those who have smoked or used nicotine products.

• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.

• History of severe allergy/hypersensitivity or ongoing clinically importantallergy/hypersensitivity.

• Statin treatment within 4 weeks prior to the start of study treatment.

• Current use of estrogen-containing products.